Compare Hershey Co (HSY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Johnson & Johnson — how do they compare? Hershey Co trades at $171.69 (market cap $34.83B), while Johnson & Johnson trades at $255.97 (market cap $603.27B). The key difference: Johnson & Johnson is far larger — about 17.3× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| HSY | JNJ | |
|---|---|---|
Market Cap | $34.83B | $603.27B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $267.24 |
52-Week Low | $162.31 | $164.74 |
Enterprise Value | $39.63B | $636.21B |
Dividend Yield | 3.38% | 2.14% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $170.63, down 0.46% on the day, with a bearish technical signal from moving averages. The company reported revenue of $11.69B for 2025 with a net income margin of 9.12%, though margins have compressed from prior years. Recent earnings have consistently beaten expectations, and the company announced a $1.45 dividend payable in June 2026. Analyst consensus is a 'Hold' with a price target of $207.82, indicating potential upside from current levels.
The outlook for HSY hinges on margin recovery as high cocoa costs cycle out. While valuation multiples appear elevated, consistent earnings beats and a solid dividend yield of approximately 3.4% provide support. Key risks include persistent volume weakness and competitive pressures. The stock presents a cautious opportunity for investors betting on a fundamental rebound in the second half of 2026.
Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.
JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
